Tags

Type your tag names separated by a space and hit enter

Review: the impacts of circulating 25-hydroxyvitamin D levels on cancer patient outcomes: a systematic review and meta-analysis.
J Clin Endocrinol Metab 2014; 99(7):2327-36JC

Abstract

CONTEXT

Circulating levels of 25-hydroxyvitamin D [25(OH)D] may affect the prognosis of cancer patients; however, the epidemiological results are not consistent.

OBJECTIVE

To perform a meta-analysis of all published studies to assess the associations of circulating 25(OH)D levels measured at or near the time of diagnosis and outcomes for cancer patients.

DATA SOURCES

Searches of the PubMed and MEDLINE databases were performed and updated to December 2013.

STUDY SELECTION

Studies reporting an association between circulating 25(OH)D levels at or near the time of diagnosis and outcomes for the patients were included.

DATA EXTRACTION

Data extraction was performed independently by two authors, and conflicts were resolved by a third investigator.

DATA SYNTHESIS

Included in the meta-analysis were 25 studies with 17 332 cases. Significant associations between circulating 25(OH)D levels at or near the time of diagnosis and the outcomes for cancer patients were found. The pooled hazard ratio for the highest vs the lowest quartile of circulating 25(OH)D levels was 0.55 (95% confidence interval [CI] = 0.33-0.91) for overall survival of colorectal cancer patients, 0.63 (95% CI = 0.51-0.77) for breast cancer patients, and 0.48 (95% CI = 0.36-0.64) for lymphoma patients. Higher 25(OH)D levels were significantly associated with reduced cancer-specific mortality for patients with colorectal cancer (P = .005) and lymphoma (P < .001) and improved disease-free survival for patients with breast cancer (P < .001) or lymphoma (P < .05). A 10-nmol/L increment in circulating 25(OH)D levels conferred a hazard ratio of 0.96 (95% CI = 0.95-0.97) for overall survival of the cancer patients.

CONCLUSIONS

The results indicate that cancer patients with higher circulating 25(OH)D levels at or near the time of diagnosis have better outcomes.

Authors+Show Affiliations

Key Laboratory of Food Safety Research (M.L., P.C., J.L., R.C., D.X., H.W.), Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, University of the Chinese Academy of Sciences, Shanghai 200031, China; Key Laboratory of Food Safety Risk Assessment (D.X., H.W.), Ministry of Health, Beijing 100021, China; and School of Life Science and Technology (D.X., H.W.), Shanghai Tech University, Shanghai, 200031, China.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't
Review
Systematic Review

Language

eng

PubMed ID

24780061

Citation

Li, Mian, et al. "Review: the Impacts of Circulating 25-hydroxyvitamin D Levels On Cancer Patient Outcomes: a Systematic Review and Meta-analysis." The Journal of Clinical Endocrinology and Metabolism, vol. 99, no. 7, 2014, pp. 2327-36.
Li M, Chen P, Li J, et al. Review: the impacts of circulating 25-hydroxyvitamin D levels on cancer patient outcomes: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2014;99(7):2327-36.
Li, M., Chen, P., Li, J., Chu, R., Xie, D., & Wang, H. (2014). Review: the impacts of circulating 25-hydroxyvitamin D levels on cancer patient outcomes: a systematic review and meta-analysis. The Journal of Clinical Endocrinology and Metabolism, 99(7), pp. 2327-36. doi:10.1210/jc.2013-4320.
Li M, et al. Review: the Impacts of Circulating 25-hydroxyvitamin D Levels On Cancer Patient Outcomes: a Systematic Review and Meta-analysis. J Clin Endocrinol Metab. 2014;99(7):2327-36. PubMed PMID: 24780061.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Review: the impacts of circulating 25-hydroxyvitamin D levels on cancer patient outcomes: a systematic review and meta-analysis. AU - Li,Mian, AU - Chen,Peizhan, AU - Li,Jingquan, AU - Chu,Ruiai, AU - Xie,Dong, AU - Wang,Hui, Y1 - 2014/04/29/ PY - 2014/5/1/entrez PY - 2014/5/2/pubmed PY - 2014/9/30/medline SP - 2327 EP - 36 JF - The Journal of clinical endocrinology and metabolism JO - J. Clin. Endocrinol. Metab. VL - 99 IS - 7 N2 - CONTEXT: Circulating levels of 25-hydroxyvitamin D [25(OH)D] may affect the prognosis of cancer patients; however, the epidemiological results are not consistent. OBJECTIVE: To perform a meta-analysis of all published studies to assess the associations of circulating 25(OH)D levels measured at or near the time of diagnosis and outcomes for cancer patients. DATA SOURCES: Searches of the PubMed and MEDLINE databases were performed and updated to December 2013. STUDY SELECTION: Studies reporting an association between circulating 25(OH)D levels at or near the time of diagnosis and outcomes for the patients were included. DATA EXTRACTION: Data extraction was performed independently by two authors, and conflicts were resolved by a third investigator. DATA SYNTHESIS: Included in the meta-analysis were 25 studies with 17 332 cases. Significant associations between circulating 25(OH)D levels at or near the time of diagnosis and the outcomes for cancer patients were found. The pooled hazard ratio for the highest vs the lowest quartile of circulating 25(OH)D levels was 0.55 (95% confidence interval [CI] = 0.33-0.91) for overall survival of colorectal cancer patients, 0.63 (95% CI = 0.51-0.77) for breast cancer patients, and 0.48 (95% CI = 0.36-0.64) for lymphoma patients. Higher 25(OH)D levels were significantly associated with reduced cancer-specific mortality for patients with colorectal cancer (P = .005) and lymphoma (P < .001) and improved disease-free survival for patients with breast cancer (P < .001) or lymphoma (P < .05). A 10-nmol/L increment in circulating 25(OH)D levels conferred a hazard ratio of 0.96 (95% CI = 0.95-0.97) for overall survival of the cancer patients. CONCLUSIONS: The results indicate that cancer patients with higher circulating 25(OH)D levels at or near the time of diagnosis have better outcomes. SN - 1945-7197 UR - http://www.unboundmedicine.com/medline/citation/24780061/full_citation L2 - https://academic.oup.com/jcem/article-lookup/doi/10.1210/jc.2013-4320 DB - PRIME DP - Unbound Medicine ER -